Valuation dashboard for Capricor Therapeutics, Inc. (CAPR) with P/E N/A, P/B 1.85, EV/EBITDA 0.52 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine.
Analysis Summary
Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.
At the current price of $8.56, CAPR has negative trailing earnings (P/E not meaningful) and an ROE of -56.60%. Market capitalisation stands at $492M.
Balance sheet quality for CAPR: current ratio of 9.0. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 1.85 |
| EV / EBITDA | 0.52 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $5.78 |
| vs Current Price | -32.5% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| CAPR | Capricor Therapeutics, Inc. | $492M | 1.85 | -56.6% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $8.56 |
| Market Cap | $492M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -56.60% |
| Return on Invested Capital | -40.08% |
| Return on Assets | -35.10% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ACHV · ALLO · ARCT · CABA · EDIT · IMMP · LXEO
Explore sector: Healthcare · Biotechnology
More sections of CAPR: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks